Gene vectors targeting CNS endothelial cells allow to manipulate the blood-brain barrier and to correct genetic defects in the CNS. Because vectors based on the adeno-associated virus (AAV) have a limited capacity, it is essential that the DNA sequence controlling gene expression is short. In addition, it must be specific for endothelial cells to avoid off-target effects. To develop improved regulatory sequences with selectivity for brain endothelial cells, we tested the transcriptional activity of truncated promoters of eleven (brain) endothelial-specific genes in combination with short regulatory elements, i.e., the woodchuck post-transcriptional regulatory element (W), the CMV enhancer element (C), and a fragment of the first intron of the Tie2 gene (S), by transfecting brain endothelial cells of three species. Four combinations of regulatory elements and short promoters (Cdh5, Ocln, Slc2a1, and Slco1c1) progressed through this in-vitro pipeline displaying suitable activity. When tested in mice, the regulatory sequences C-Ocln-W and C-Slc2a1-S-W enabled a stronger and more specific gene expression in brain endothelial cells than the frequently used CAG promoter. In summary, the new regulatory elements efficiently control gene expression in brain endothelial cells and may help to specifically target the blood-brain barrier with gene therapy vectors.
KirschenGWKeryRLiuH, et al.
Genetic dissection of the neuro-glio-vascular machinery in the adult brain. Mol Brain2018;
11: 2.
2.
HaeryLDevermanBEMathoKS, et al.
Adeno-associated virus technologies and methods for targeted neuronal manipulation. Front Neuroanat2019;
13: 93.
3.
ChakrabartyPRosarioACruzP, et al.
Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain. PLoS One2013;
8: e67680.
4.
VagnerTDvorzhakAWojtowiczAM, et al.
Systemic application of AAV vectors targeting GFAP-expressing astrocytes in Z-Q175-KI huntington's disease mice. Mol Cell Neurosci2016;
77: 76–86.
5.
WuZParryMHouXY, et al.
Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of huntington's disease. Nat Commun2020;
11: 1105.
6.
CouchaMBarrettACElgebalyM, et al.
Inhibition of Ephrin-B2 in brain pericytes decreases cerebral pathological neovascularization in diabetic rats. PLoS One2019;
14: e0210523.
7.
RosarioAMCruzPECeballos-DiazC, et al.
Microglia-specific targeting by novel capsid-modified AAV6 vectors. Mol Ther Methods Clin Dev2016;
3: 16026.
8.
DogbeviaGKTöllnerKKörbelinJ, et al.
Gene therapy decreases seizures in a model of incontinentia pigmenti. Ann Neurol2017;
82: 93–104.
9.
DogbeviaGGrasshoffHOthmanA, et al.
Brain endothelial specific gene therapy improves experimental Sandhoff disease. J Cereb Blood Flow Metab2020;
40: 1338–1350.
10.
SweeneyMDZhaoZMontagneA, et al.
Blood-brain barrier: from physiology to disease and back. Physiol Rev2019;
99: 21–78.
11.
ObermeierBDanemanRRansohoffRM.Development, maintenance and disruption of the blood-brain barrier. Nat Med2013;
19: 1584–1596.
12.
RidderDAWenzelJMüllerK, et al.
Brain endothelial TAK1 and NEMO safeguard the neurovascular unit. J Exp Med2015;
212: 1529–1549.
13.
TangMGaoGRuedaCB, et al.
Brain microvasculature defects and Glut1 deficiency syndrome averted by early repletion of the glucose transporter-1 protein. Nat Commun2017;
8: 14152.
14.
VatineGDAl-AhmadABarrigaBK, et al.
Modeling psychomotor retardation using iPSCs from MCT8-Deficient patients indicates a prominent role for the Blood-Brain barrier. Cell Stem Cell2017;
20: 831–843. e835.
15.
ChenYHChangMDavidsonBL.Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med2009;
15: 1215–1218.
16.
ChenYHClaflinKGeogheganJC, et al.
Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol Ther2012;
20: 1393–1399.
17.
DomengerCGrimmD.Next-generation AAV vectors-do not judge a virus (only) by its cover. Hum Mol Genet2019;
28: R3–R14.
18.
NaultJCDattaSImbeaudS, et al.
Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet2015;
47: 1187–1193.
19.
La BellaTImbeaudSPeneauC, et al.
Adeno-associated virus in the liver: natural history and consequences in tumour development. Gut2020;
69: 737–747.
20.
KörbelinJDogbeviaGMichelfelderS, et al.
A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases. EMBO Mol Med2016;
8: 609–625.
21.
MüllerOJLeuchsBPlegerST, et al.
Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res2006;
70: 70–78.
22.
ReynoldsPNNicklinSAKaliberovaL, et al.
Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol2001;
19: 838–842.
23.
LiuDZhuMZhangY, et al.
Crossing the blood-brain barrier with AAV vectors. Metab Brain Dis2021;
36: 45–52.
24.
AssmannJCKörbelinJSchwaningerM.Genetic manipulation of brain endothelial cells in vivo. Biochim Biophys Acta2016;
1862: 381–394.
25.
DanemanRZhouLAgalliuD, et al.
The mouse blood-brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. PLoS One2010;
5: e13741.
26.
RidderDALangMFSalininS, et al.
TAK1 in brain endothelial cells mediates fever and lethargy. J Exp Med2011;
208: 2615–2623.
27.
NiuCChenZKimKT, et al.
Metformin alleviates hyperglycemia-induced endothelial impairment by downregulating autophagy via the hedgehog pathway. Autophagy2019;
15: 843–870.
28.
WhiteSJPapadakisEDRogersCA, et al.
In vitro and in vivo analysis of expression cassettes designed for vascular gene transfer. Gene Ther2008;
15: 340–346.
29.
MimuroJMuramatsuSHakamadaY, et al.
Recombinant adeno-associated virus vector-transduced vascular endothelial cells express the thrombomodulin transgene under the regulation of enhanced plasminogen activator inhibitor-1 promoter. Gene Ther2001;
8: 1690–1697.
30.
de LeeuwCNKoreckiAJBerryGE, et al.
rAAV-compatible MiniPromoters for restricted expression in the brain and eye. Mol Brain2016;
9: 52.
31.
SaundersAMacoskoEZWysokerA, et al.
Molecular diversity and specializations among the cells of the adult mouse brain. Cell2018;
174: 1015–1030.
32.
ZhangYChenKSloanSA, et al.
An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci2014;
34: 11929–11947.
33.
BosmaEKvan NoordenCJFSchlingemannRO, et al.
The role of plasmalemma vesicle-associated protein in pathological breakdown of blood-brain and blood-retinal barriers: potential novel therapeutic target for cerebral edema and diabetic macular edema. Fluids Barriers CNS2018;
15: 24.
GorySVernetMLaurentM, et al.
The vascular endothelial-cadherin promoter directs endothelial-specific expression in transgenic mice. Blood1999;
93: 184–192.
36.
NordeenSK.Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechniques1988;
6: 454–458.
37.
KüglerSLingorPSchöllU, et al.
Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Virology2003;
311: 89–95.
38.
XiaoXLiJSamulskiRJ.Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol1998;
72: 2224–2232.
39.
GrimmDKayMAKleinschmidtJA.Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther2003;
7: 839–850.
40.
AssmannJCMüllerKWenzelJ, et al.
Isolation and cultivation of primary brain endothelial cells from adult mice. Bio Protoc2017;
7: e2294.
41.
PatabendigeASkinnerRAMorganL, et al.
A detailed method for preparation of a functional and flexible blood-brain barrier model using porcine brain endothelial cells. Brain Res2013;
1521: 16–30.
42.
WekslerBBSubileauEAPerrièreN, et al.
Blood-brain barrier-specific properties of a human adult brain endothelial cell line. Faseb J2005;
19: 1872–1874.
43.
DrüppelVKusche-VihrogKGrossmannC, et al.
Long-term application of the aldosterone antagonist spironolactone prevents stiff endothelial cell syndrome. Faseb j2013;
27: 3652–3659.
44.
SchlaegerTMBartunkovaSLawittsJA, et al.
Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci U S A1997;
94: 3058–3063.
45.
WuZSunJZhangT, et al.
Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther2008;
16: 280–289.
46.
De PalmaMVenneriMANaldiniL.In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther2003;
14: 1193–1206.
47.
ParienteNMaoSHMorizonoK, et al.
Efficient targeted transduction of primary human endothelial cells with dual-targeted lentiviral vectors. J Gene Med2008;
10: 242–248.
48.
DubeAAkbaraliYSatoTN, et al.
Role of the Ets transcription factors in the regulation of the vascular-specific Tie2 gene. Circ Res1999;
84: 1177–1185.
49.
KleinRRuttkowskiBKnappE, et al.
WPRE-mediated enhancement of gene expression is promoter and cell line specific. Gene2006;
372: 153–161.
50.
SabbaghMFNathansJ.A genome-wide view of the de-differentiation of central nervous system endothelial cells in culture. Elife2020;
9: e51276.
51.
DimidschsteinJChenQTremblayR, et al.
A viral strategy for targeting and manipulating interneurons across vertebrate species. Nat Neurosci2016;
19: 1743–1749.
52.
JüttnerJSzaboAGross-ScherfB, et al.
Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans. Nat Neurosci2019;
22: 1345–1356.
53.
Meireles-FilhoACAStarkA.Comparative genomics of gene regulation—conservation and divergence of cis-regulatory information. Curr Opin Genet Dev2009;
19: 565–570.
54.
KuzminDAShutovaMVJohnstonNR, et al.
The clinical landscape for AAV gene therapies. Nat Rev Drug Discov2021;
20: 173–174.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
